Introduction

In the last few years, mTOR inhibitors such as rapamycin or its derivative everolimus are increasingly used as potent immunosuppressants in renal and cardiac transplant therapy [1].

Chronic allograft nephropathy (CAN) is the main cause of renal allograft loss after one year of transplantation. Despite the impact of modern immunosuppression on reducing acute graft rejection, there has been little impact on long-term graft survival [2,3]. Some investigators propose that mTOR inhibitors can contribute on reducing CAN progression [4].

Although the pathogenesis of chronic damage responsible for CAN is still largely unclear both immune and non-immune mechanisms may participate and they are characterized by an inflammatory response and the subsequent release of profibrotic cytokines and growth factor within the kidney [5]. Chronic interstitial fibrosis, tubular atrophy, vascular occlusive changes and glomerulosclerosis are the common final pathway leading to progressive renal dysfunction and to end-stage renal failure [6]. Profibrotic mediators such as TGFβ mainly produced by epithelial cells, may prime their transdifferentiation into fibroblasts and their subsequent activation, directly leading to interstitial fibrosis [7].
TGFB also stimulates matrix production and reduces its degradation. The severity of tubulointerstitial inflammation and fibrosis have long been considered as crucial determinants in the pathogenesis of renal fibrosis and in long-term prognosis of both human and experimental chronic nephropathies regardless of the initial cause [8,9].

mTOR is a major downstream component in the phosphoinositide 3-kinase pathway (PI3K), and has emerged as one of the main signalling routes utilized by cells to control their growth, proliferation, differentiation, migration, organization and survival [10]. In addition to lymphocytes, mTOR inhibitors act as anti proliferative for several other cell types such as vascular smooth muscle cells, mesangial, tubular and endothelial cells. Massive urinary protein excretion has been observed in renal transplant recipients with CAN after conversion from calcineurin inhibitors to mTOR inhibitors, especially sirolimus [11]. High range proteinuria has been observed during sirolimus therapy in patients who received sirolimus de novo [12,13]. Podocyte injury and focal segmental glomerulosclerosis have been related to mTOR inhibition in some patients, but the pathways underlying these lesions remain hypothetic [14,15].

Controversy exists about the beneficial effects of mTOR inhibition in experimental nephropathies with some reports showing that it may be useful to diminish progression [16,17] and others reporting increase in proteinuria and aggravation of renal disease [18,19].

The model of mass reduction with right nephrectomy plus ligation of two branches of the left renal artery (5/6 nephrectomy) has been extensively used to study renal disease progression. Rats with 5/6 nephrectomy develop severe hypertension, proteinuria and progression to end stage renal disease [20–22].

The effect of mTOR inhibitors on disease progression in this model also is controversial. Diekmann et al [23] have reported that mTOR inhibitors reduce progression, whereas Vogelbacher et al [19], using the same experimental model, reported that everolimus worsened chronic disease progression.

The aim of this study was to analyze the effects of delayed mTOR inhibition on progression of renal disease in the 5/6 nephrectomy model in Wistar rats, using a low dose of everolimus and proteinuria and microalbuminuria from animals at week 8 of treatment.

### Results

**Everolimus treatment decreased proteinuria and albuminuria without changes in blood pressure**

Blood pressure, BUN, plasma creatinine, plasma bicarbonate and proteinuria were significantly lower and creatinine clearance was significantly higher in sham group (SG) when compared with control group (CG) and everolimus-treated group (EveG) (table 1). There were no blood pressure, plasma creatinine and creatinine clearance in CG vs EveG. Anyway, EveG showed significant lower proteinuria (142.3±94.8 vs 279.3±125.3 mg/ day, p<0.05), protein creatinine ratio (14.45±8.48 vs 28.3±7.47 mg/mg, p<0.05) and urine albumin (6.83±4.6 vs 12.9±4.9 mg/ml, p<0.05) than CG (table 1).

**Everolimus diminished glomerulosclerosis and tubulointerstitial damage in the remnant kidney**

Histological analysis showed less glomerulosclerosis (GS) in EveG compared with CG when evaluated with PAS stain (0.3±0.4 vs 1.4±0.73, p<0.05), and with Masson’s stain (0.47±0.45 vs 1.25±0.8, p<0.05). There was also less tubulointerstitial (TI) damage in EveG compared with CG (2.46±1.49 vs. 6.53±1.07, p<0.05) in PAS stain and in Masson’s stain (0.1±0.09 vs. 0.24±0.16, p<0.05) (Figure 1 and table 2).

Proteinuria is related with the magnitude of tubulointerstitial (TI) damage. When we considered all the animals together, the relationship between proteinuria (mg/day) and TI score, evaluated by Masson’s stain, showed a regression coefficient of 0.86, (R2 0.73 p<0.05).

### Everolimus diminished glomerular hypertrophy, mesangial fibrosis and tubulointerstitial fibrosis in the remnant kidney

Renal fibrosis was also assessed by morphometric analysis of renal tissue stained with Sirius red. Data from morphometric analysis are given as mean ± SD and as frequency distribution, as fibrosis develops in a focal and segmental pattern and its distribution does not show a gaussian pattern. Figure 2A reveals that the CG has a more intense staining with Sirius red than the SG group, being the staining in EveG lower that in CG. Frequency distribution of glomerular area shows that SG have the cross-sectional area of all the glomeruli assessed grouped around 400 μm², whereas CG and EveG showed a wider distribution, with almost all values over 12000 μm² (Figure 2b).

The CG showed a higher glomerular area than the SG (21405±6612 vs 10533±1983 μm², p<0.05) whereas treatment with everolimus significantly diminished glomerular hypertrophy (18132±5056 μm²) although it remained significantly higher than the SG (p<0.05) (figure 2).

Figure 2c reveals that data of glomerular (mesangial) fibrosis in the SG group was grouped around 200 μm² whereas data of mesangial fibrosis in CG group showed a spread distribution with higher values, and data from the EveG showed more grouped data around 400 μm². Statistical analysis reveals that the CG showed more mesangial fibrosis than the SG (1153.7±566.2 vs 185.6±104.8 μm², p<0.05). Treatment with everolimus significantly diminished mesangial fibrosis when compared with CG (429.6±283.9 vs 1153.7±566.2, μm², p<0.05).

Figure 2d shows that the changes in tubulo-interstitial fibrosis in the studied groups show changes similar to those observed in glomerulosclerosis. The CG showed significantly more interstitial fibrosis than SG (2823.3±1424.2 vs. 483.3±505.1 μm², p<0.05), and the group treated with everolimus showed lower interstitial fibrosis than CG (897.4±499.6 μm², p<0.05) although it was significantly higher than the SG (p<0.05) (Figure 2).

### Table 1. Weight, blood pressure, renal function, proteinuria and microalbuminuria from animals at week 8 of treatment.

|                | SG | CG | EveG |
|----------------|----|----|------|
| Weight, g      | 360.6±28.4 | 353.3±48 | 355.6±26 |
| Blood Pressure, mmHg | 125±15 | 162±25* | 161±25* |
| Left Kidney weight, g | 1.4±0.2 | 2.7±0.8* | 2.25±0.36* |
| BUN, mg/dl    | 21±7 | 49±40 | 40±11 |
| Creatinine, mg/dl | 0.4±0.1 | 0.78±0.48 | 0.64±0.13 |
| Cr Cl, ml/min  | 0.52±0.2 | 0.34±0.11* | 0.32±0.12* |
| Proteinuria, mg/d | 11.3±13 | 279.3±125* | 142±95† |
| Albuminuria, mg/ml | 12.9±4.9 | 6.83±4.6* |
| uPCR, mg/mg    | 0.96±1.1 | 28.3±7.47* | 14.45±8.48† |

**PLOS ONE** | www.plosone.org | 2 March 2012 | Volume 7 | Issue 3 | e32516

DOI: 10.1371/journal.pone.0032516.t001
Figure 1. Immunohistochemistry: fibrosis, cell proliferation and inflammation. Representative results from the different groups are shown: Sham Group (A,D,G,J), Control Group (B,E,H,K) and Everolimus Group (C,F,I,L). PAS tinction (200×) (A,B,C), Immunohistochemistry for α smooth muscle actin (200×) (D,E,F), Glomerular and tubulointerstitial proliferating cell nuclear antigen (PCNA) immunostaining (200×) (G,H,I) and anti CD68 (400×) (J,K,L). Sections were counterstained with eosin.
doi:10.1371/journal.pone.0032516.g001

Table 2. Histological and immunohistochemistry semiquantitative analysis.

| Stains                  | SG          | CG            | EveG         |
|-------------------------|-------------|---------------|--------------|
|                         | n=7         | n=11          | n=8          |
| **Periodic Acid-Schiff**|             |               |              |
| G                       | 0.06±0.09   | 1.40±0.73*    | 0.30±0.43*†  |
| Ti                      | 0.00±0.00   | 6.53±1.07*    | 2.46±1.49†   |
| **Masson’s trichrome**  |             |               |              |
| GS                      | 0.00±0.00   | 1.25±0.80*    | 0.47±0.45†   |
| TIF                     | 0.00±0.00   | 0.24±0.16*    | 0.10±0.09†   |
| **Sirius Red**          |             |               |              |
| MF                      | 185.6±104   | 1153.7±566.2* | 429.6±283.9† |
| IF                      | 483.5±305.1 | 2823.3±1424.2| 897.4±499.6† |
| **α-Actine**            |             |               |              |
| G                       | 0.01±0.02   | 0.86±0.71*    | 0.19±0.14†   |
| Ti                      | 0.00±0.00   | 2.06±0.55*    | 1.03±0.52†   |
| **PCNA**                |             |               |              |
| G                       | 0.05±0.05   | 6.00±5.37*    | 2.9±3†       |
| Ti                      | 0.5±0.5     | 51.60±29.0*   | 20±20†       |
| **CD-68**               |             |               |              |
| I                       | NA          | 5.68±3.85     | 5.05±5.48    |

doi:10.1371/journal.pone.0032516.t002
Figure 2. Morphometric analysis of glomerular hypertrophy and kidney fibrosis. Panel A. Representative images from histological sections stained with Sirius red: Sham Group (A), Control Group (B) and Everolimus Group (C) (magnification 200×). Panel B. Glomerular area (mean and SD) and frequency distribution diagram of glomerular area. Panel C. Mesangial fibrosis area (mean and SD) and frequency distribution diagram of mesangial fibrosis area in the three groups. Panel D. Tubulointerstitial fibrosis area (mean and SD) and frequency distribution diagram of tubulointerstitial fibrosis area in the three groups. * p<0.05 vs sham group and †p<0.05 vs control group.

doi:10.1371/journal.pone.0032516.g002
Everolimus diminished the expression of α smooth muscle actin and cellular proliferation

We evaluated the effect of everolimus on glomerular expression and TI expression of α smooth muscle actin. The EveG showed less staining at glomerular level (0.19 ± 0.14 vs 0.86 ± 0.71, p < 0.05) and TI level (1.03 ± 0.52 vs 2.06 ± 0.55, p < 0.05) when compared with CG (Figure 1 and table 2).

Glomerular and TI PCNA staining was significantly reduced in the EveG compared with CG (2.95 ± 1 UR vs 1.19 ± 0.7 UR, p < 0.05) and (20 ± 20 vs 51.6 ± 29, p < 0.05) respectively (Figure 1).

Everolimus diminished the expression of α smooth muscle actin and cellular proliferation

mTOR mRNA increased in the remnant kidney model and it was attenuated with Everolimus treatment

mTOR mRNA is over expressed more than 4-fold in CG when compared with SG (3.95 ± 1 UR vs 1.19 ± 0.7 UR, p < 0.05). This increase is blunted in the EveG (1.2 ± 1 UR vs GC, p < 0.05) (Figure 3). There were no differences in Akt mRNA among the three groups (SG: 1.13 ± 0.8, CG: 1.5 ± 0.8 and EveG: 1.2 ± 0.3). pAkt/Akt protein abundance ratio was significantly higher in CG (151.5 ± 17) and EveG (169 ± 18.4) than SG (100 ± 12, p < 0.05) but without differences among them (Figure 3 and Figure 4).

Everolimus blunted the increased expression of TGFβ observed in the remnant kidney model

TGFβ mRNA significantly increased in the CG when compared with SG (4.7 ± 2.8 vs 0.8 ± 0.4 UR, p < 0.05). TGFβ in the EveG returned to the SG levels of expression (0.8 ± 0.4 UR, p < 0.05 vs GC) (Figure 4).

There were no differences in pERK/ERK ratio among the different groups.

Discussion

Treatment with everolimus 0.3 mg/kg/day for 8 weeks starting two weeks after 5/6 nephrectomy significantly reduced proteinuria, albuminuria, glomerular and tubulo-interstitial fibrosis, fibroblast proliferation and/or activation, and cellular proliferation.

It also significantly diminished glomerular hypertrophy. Rovira et al showed that sirolimus treatment before 5/6 nephrectomy diminished glomerular hypertrophy but the treatment after nephrectomy was unable to reduce hypertrophy [24]. As far as we know this is the first evidence that everolimus given after 5/6 nephrectomy reduced glomerular hypertrophy, one of the main contributors to glomerulosclerosis in this model [24].

As the fibrosis process develops in a focal and segmental pattern we decided to show the frequency distribution of fibrosis areas in the tissue (panels b, c and d, figure 2). These graphics allows us to visualize the magnitude of fibrosis in the different experimental groups.

There were no differences in renal function between CG and EveG, probably related with the limited follow up time in our model. Other authors using a rat model of polycystic kidney disease were able to show preservation of renal function after prolonged treatment with rapamycin [25].

We found a fourfold increase in mTOR mRNA expression in the remnant kidney model compared with SG. Treatment with everolimus significantly prevented this increase. We can speculate that this inhibition of mTOR mRNA is related with the known

Figure 3. Western blot and protein abundance ratio for pAkt/total Akt and pERK/total ERK. A) Immunoblotting analysis for Total Akt 1–2 and phospho-Akt (Ser473); B) Densitometric analysis of pAkt/total Akt; SG (n = 7), CG (n = 5) and EveG (n = 6); C) Immunoblotting analysis for ERK 1/2 and phospho-ERK (E-4); D) Densitometric analysis of pERK/total ERK. SG (n = 7), CG (n = 5) and EveG (n = 6). * p < 0.05 vs sham group.

Figure 4. mRNA expression for Akt, mTOR and TGFβ. Relative mRNA expression levels of Akt, mTOR and TGFβ were assessed by real time quantitative reverse transcriptase-PCR in remnant kidneys of SG (n = 7), CG (n = 5) and EveG (n = 7). * p < 0.05 vs sham, ** p < 0.05 vs CG.

doi:10.1371/journal.pone.0032516.g003

doi:10.1371/journal.pone.0032516.g004
transcriptional downregulation effect of mTOR inhibition. In this way mTOR inhibitors prevented the production of new mTOR, diminishing the amount of mTOR available for new mTOR complex formation.

The increase in mTOR mRNA in the remnant kidney model can play a key role in progression of renal disease. mTOR phosphorylation increases mRNA translation via activation of S6 kinase 1 (S6K1) and inhibition of the eukaryotic initiation factor 4E–binding protein1 (4E-BP1), enhancing protein production and cell proliferation [26,27].

The well known increase in mRNA TGFβ expression observed in the remnant kidney model [28,29] is completely blunted by everolimus. These results contrast with nephrotoxicity models in normal rats, in which sirolimus increases TGFβ [30]. TGFβ inhibition can partially explain the observed anti-fibrotic effects of everolimus. These results are in accordance with the referred effects of mTOR inhibition in fibroblast activation by TGFβ [27]. Junaid showed, in the 5/6 nephrectomy model, an increase in mRNA TGFβ and protein abundance for TGFβ by elisa, when compared with the sham group. This increase was blocked with losartan [22]. Recent reports indicate that one of the most relevant noncanonical TGFβ pathways is mTORC1 [31], giving more relevance to our findings that mTOR inhibition can affect TGFβ production and signalling.

We found a significant increase in pAkt/tAkt(308) ratio in the CG, consistent with the stimulation off mTOR signaling pathway and also mTORC2 in this model. Recently Sarbassov showed that prolonged exposition to rapamycin is able to inhibit mTORC2 [32]. We were not able to show this inhibition as the treatment with everolimus didn’t modified Akt phosphorylation. One alternative explanation to Sarbassov’s findings may be that a prolonged exposition to mTOR inhibitors can reduce mTOR availability by means of mTOR mRNA reduction.

On the other hand, Vogelbacher et al [19] using the same experimental model reported that everolimus (2.5 mg/kg/d) introduced 3 days after nephrectomy worsened chronic disease progression. These results were the consequence of a markedly increased fraction of glomeruli with a defective glomerular architecture in the everolimus group. Everolimus apparently inhibited the glomerular repair reaction via proliferative activity inhibition of the glomerular endothelial and mesangial cells and it was associated with reduced glomerular vascular endothelial growth factor mRNA and protein abundance [19]. A recent review [33] highlighted that rapamycin delays recovery and repair of experimental acute kidney Injury [34] and causes and/or exacerbates delay graft function [35].

We used a dose of everolimus more than 8 folds lower than Vogelbacher et al [19]. Dose election was based in preliminary data using different doses (5, 3, 1 and 0.3 mg/kg/day). The animals treated with higher doses showed higher mortality rate and severe adverse effects: diarrhea, weight loss, arrest in wounds healing, and encapsulated abdominal abscess that were not observed with 0.3 mg/kg/day.

We believe that the earlier introduction of high dose everolimus can not only aggravate a pre existent nephropathy but can also produce a new and more aggressive experimental model of nephropathy. Letavernier et al., reported that high sirolimus levels may induce focal and segmental glomerulosclerosis de novo [36]. Our results are in accordance with those reported by other groups working with the same model. Diekmann et al reported that animals treated with sirolimus had less glomerulosclerosis, tubulointerstitial damage and attenuated the increased expression of renal vascular endothelial growth factor [23]. Nakagawa et al. described that everolimus administration suppressed smooth muscle actin, macrophage infiltration and kidney injury molecule-1expression in the proximal tubules [37]. Torras et al. demonstrated a higher glomerular podocin and nephrin expression and amelioration of glomerular ultrastructural damage in the ramyapcin group [15].

Beneficial effects of mTOR inhibitors were also reported in anti-thy1 nephritis [17], in experimental membranous nephropathy [30], in adriamycin induced nephropathy [39], in unilateral obstructive uropathy [40] and in the murine model of renal polycystic disease [41]. In diabetes induced by streptozotocin [16] sirolimus treatment produced a reduction of albuminuria and the expression of renal mTOR and TGFβ.

Our findings provide in vivo evidence that everolimus significantly prevented progressive renal fibrosis and protected the remnant kidney in an experimental model of reduced renal mass. In order to obtain these beneficial effects everolimus should be administrated after the acute effects of renal ablation and reparation have taken effect and in a lower dose than previously described.

The mTOR and TGFβ inhibition can partially explain the anti-fibrotic effects produced by everolimus.

This study supports that mTOR can be a possible new target to attenuate the progression of chronic kidney disease [4].

Methods

Model and experimental design

All the animals were handled according to the Principles of the Laboratory Animal Care (National Institutes of Health, 1985). The experimental protocol was approved by the University Animal Experimental Committee and by the local ethic committee. The animals were housed in individual cages in a constant-temperature room with 12:12-h dark-light and free access to water and food with a normal protein diet (24%). Rats were anesthetized with sodium thiopental 35 mg/kg i.p for all surgical procedures.

Male Wistar rats with an initial body weight of 300±30 g were used for this study. Initially, simultaneous systolic blood pressure and pulse in the awake animal were registered by the tail cuff method using CVMS-20 software (World Precision Instruments, Sarasota, FL, USA).

Rats were randomly assigned to 3 groups. Two of these groups underwent 5/6 nephrectomy by selective ligation of renal artery branches followed by contra lateral nephrectomy. SG underwent abdominal incision and manipulation of both kidneys without excision.

Two weeks after nephrectomy the EveG received everolimus 0.3 mg/kg/day or vehicle for CG, administered by daily gavages during 8 weeks. Dose election was based in a preliminary study using different doses (5, 3, 1 and 0.3 mg/kg/day). The animals treated with higher doses showed higher mortality rate and severe adverse effects: diarrhea, weight loss, arrest in wounds healing, and encapsulated abdominal abscess that were not observed with 0.3 mg/kg/day.

We believe that the earlier introduction of high dose everolimus can not only aggravate a pre existent nephropathy but can also produce a new and more aggressive experimental model of nephropathy. Letavernier et al., reported that high sirolimus levels may induce focal and segmental glomerulosclerosis de novo [36]. Our results are in accordance with those reported by other groups working with the same model. Diekmann et al reported that animals treated with sirolimus had less glomerulosclerosis, tubulointerstitial damage and attenuated the increased expression of renal vascular endothelial growth factor [23]. Nakagawa et al. described that everolimus administration suppressed smooth muscle actin, macrophage infiltration and kidney injury molecule-1expression in the proximal tubules [37]. Torras et al. demonstrated a higher glomerular podocin and nephrin expression and amelioration of glomerular ultrastructural damage in the ramyapcin group [15].

Beneficial effects of mTOR inhibitors were also reported in anti-thy1 nephritis [17], in experimental membranous nephropathy [30], in adriamycin induced nephropathy [39], in unilateral obstructive uropathy [40] and in the murine model of renal polycystic disease [41]. In diabetes induced by streptozotocin [16] sirolimus treatment produced a reduction of albuminuria and the expression of renal mTOR and TGFβ.

Our findings provide in vivo evidence that everolimus significantly prevented progressive renal fibrosis and protected the remnant kidney in an experimental model of reduced renal mass. In order to obtain these beneficial effects everolimus should be administrated after the acute effects of renal ablation and reparation have taken effect and in a lower dose than previously described.

The mTOR and TGFβ inhibition can partially explain the anti-fibrotic effects produced by everolimus.

This study supports that mTOR can be a possible new target to attenuate the progression of chronic kidney disease [4].

Methods

Model and experimental design

All the animals were handled according to the Principles of the Laboratory Animal Care (National Institutes of Health, 1985). The experimental protocol was approved by the University Animal Experimental Committee and by the local ethic committee. The animals were housed in individual cages in a constant-temperature room with 12:12-h dark-light and free access to water and food with a normal protein diet (24%). Rats were anesthetized with sodium thiopental 35 mg/kg i/p for all surgical procedures.

Male Wistar rats with an initial body weight of 300±30 g were used for this study. Initially, simultaneous systolic blood pressure and pulse in the awake animal were registered by the tail cuff method using CVMS-20 software (World Precision Instruments, Sarasota, FL, USA).

Rats were randomly assigned to 3 groups. Two of these groups underwent 5/6 nephrectomy by selective ligation of renal artery branches followed by contra lateral nephrectomy. SG underwent abdominal incision and manipulation of both kidneys without excision.

Two weeks after nephrectomy the EveG received everolimus 0.3 mg/kg/day or vehicle for CG, administered by daily gavages during 8 weeks. Dose election was based in a preliminary study using different doses (5, 3, 1 and 0.3 mg/kg/day). The animals treated with higher doses showed higher mortality rate and severe adverse effects: diarrhea, weight loss, arrest in wounds healing, and encapsulated abdominal abscess that were not observed with 0.3 mg/kg/day. Meanwhile, recent reports have described the use of a lower dose of everolimus in order to reduce mortality [42].

Everolimus for oral administration was provided by Novartis Pharmaceuticals, Inc.

Functional and Histological studies

The rats were assigned to 3 groups: SG (n = 7), CG (n = 11) and EveG (n = 8). After 8 weeks of treatment 24 hours urine collection was performed and simultaneous systolic blood pressure and pulse were registered. The remnant left kidney was immediately
perfused with phosphate-buffered saline at 4°C and 4% paraformaldehyde, and stored for renal morphology and immunohistochemistry studies.

Serum creatinine, BUN, plasma bicarbonate, urinary protein, albumin, low weight molecular protein excretion and creatinine clearance were determined.

Sample storage for RNA and protein extraction purposes

We performed the same experimental procedure with three new groups of animals: SG (n=7), CG (n=5) and EveG (n=7) to obtain renal tissue for real time RT PCR and Western blot. At week 8 remnant kidney was perfused with cold PBS. The kidney was removed and renal cortex excised, snap-frozen in liquid nitrogen and stored at −80°C until processing.

Analytical methods

Serum and urinary creatinine were measured by the buffered kinetic Jaffe reaction. BUN was determined by spectrophotometric method, plasma bicarbonate with a blood analyzer (ABL 700, Radiometer, Copenhagen, Denmark) and urinary protein excretion was assayed by the turbidimetric method with sulfosalicylic acid. Albuminuria and low weight proteinuria were assessed by High Performance Liquid Cromatography according to Turpeinen [43].

Quantification of renal histology

Coronal sections of the kidney were immersion-fixed in paraformaldehyde solution and embedded in paraffin. Light microscopy was performed on 4-μm sections of tissue stained with periodic acid-Schiff’s (PAS) and Masson trichrome reagent (MT) to assess GS and TI fibrosis. GS was assessed by semi quantitative analysis of 20 consecutive glomeruli (400×) according to El Nahas et al [44]. GS was defined as glomeruli with sclerosis or mesangial expansion and/or focal hyalinosis with tuft adherence. Glomerulosclerosis was graded from 0 to 4 by a semi quantitative score: grade *0) normal, *1) mesangial expansion/sclerosis involving less than 25% of the glomerular tuft, *2) moderate GS (25%–50%), *3) severe GS (50%–75%), and grade *4 diffuse GS (more than 75%). TI damage was evaluated using a semi quantitative analysis of 20 cortical fields (200×) according to Veniant et al [45]. Lesions were graded from 0 to 4 according to the area with tubulointerstitial changes (tubular atrophy, casts, interstitial inflammation, and fibrosis).

The score index in each rat was expressed as a mean value of all scores obtained.

All the histological analysis were performed by an observer unaware of the treatment received by each group.

Morphometric studies

Morphometric studies were performed in sections 5 μm thick and Sirius Red stained. In brief, images were captured at 20-fold magnification using a green optical filter (IF 550) and a high-resolution videocamera (SONY CCD-iris) connected to a light microscope (Nikon, Eclipse 50i). The evaluation and image analysis procedures were performed with specific software [46].

As Sirius Red stains collagen fibers, the program automatically transforms color images in 256 grey levels images and quantifies the elements of the image, previously isolated from the background. In the case of glomerular images, it is necessary to split the corpuscular area by indicating in the monitor where the glomerulus is located. Then the program automatically discriminates the area of renal corpuscles which is usually surrounded by a pericapsular coat of fibers that are stained by Sirius Red.

A total of 25 glomerular images and 10 interstitial images random fields of renal slides (n=5 animals per group) were captured and processed. The values obtained for each image were: a) glomerular fibrotic area or percentage of Sirius red-stained area which is contained in Bowman’s capsule, b) renal corpuscular area and c) interstitial fibrotic area, or percentage of tubulointerstitial area occupied by Sirius red staining (excluding glomeruli and big arteries). These values, saved in data ASCII files conveniently labeled, can be exported to any statistical analyses program and calculate several parameters that can express the degree of renal fibrosis and glomerular sclerosis in an objective and quantitative way.

Quantification of immunohistochemistry

Sections of paraformaldehyde fixed kidney tissues were processed by indirect immune detection technique with Biotin streptavidin amplified detection system (BioGenex, San Ramon, CA, USA) using three primary antibodies: (1) proliferating nuclear cell antigen (PCNA) (Dako Glostrup, Denmark NP047) (dilution 1:200), as a marker of cell proliferation, (2) α smooth muscle actin as a marker of myofibroblast transformation (Dako Glostrup, Denmark NP025) (dilution 1:100) and (3) CD68 as a marker of macrophages (Serotec, Oxford, UK MCA341R) (dilution 1:100). Next, samples were incubated with secondary antibody conjugated with peroxidase, EnVision® (DAKO, Glostrup, Denmark) for 30 minutes and stained with DAB (EnVision®, DAKO®, Glostrup, Denmark). Tissues were counter stained with hematoxilin.

Normal rabbit IgG (Santa Cruz Biotecnology, Santa Cruz, CA, USA) was used as a negative control. Mean score per biopsy was calculated as follows: glomerular PCNA and CD68 as the mean number of positive cells in 20 glomeruli (cells/glomerular cross section) (400×), CD68 and PCNA tubular/interstitial score was obtained as the mean number of stained cells in 20 fields (cells/fields) (200×).

For the evaluation of α-smooth muscle actin each glomerulus and tubulointerstitial field was graded semi quantitatively according to the extent of the staining from 0 (absent) to 4 more than 75% in the glomerular tuft or more than 75% of tubulointerstitial field. Mean scores of 20 glomeruli and 20 fields were calculated. Immunohistochemistry images were acquired (SnapCool-Pro, Nikon®, Tokio, Japan) and digital analysis was performed (Image-Pro-Plus, Version 4.05 Media Cybernetics Bethesda, MD, USA).

Western Blot Analysis of Akt, phospho-Akt, ERK and phospho-ERK

Tissue protein extracts were homogenized in lysis buffer (25 mM HEPES pH7.5, 150 mM NaCl, 1% Igepal CA-630, 10 mM MgCl2, 1 mM EDTA, 10% glycerol, 10 μg/mL aprotinin, 10 μg/mL leupeptin, 100 mM PMSF, 25 mM NaF, 1 mM Na3VO4) and centrifuged at 14,000 g for 30 min. Supernatant was recovered and proteins were quantified. Western blot analysis was performed as previously described [49]. In brief lysates (60 μg/lane) were loaded onto SDS-polyacrylamide gels, and the proteins were transferred to nitrocellulose membranes (Bio-Rad) by electroblotting. Membranes blocked in TTBS (10 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween 20 plus 2% bovine serum albumin) were incubated overnight at 4°C, as appropriate, with: anti-Akt1/2 (dilution 1:1000, sc-8312, Santa Cruz Biotechnology, Inc. Santa Cruz, Temeccula CA, USA), anti-phospho-Akt (Ser 473) (dilution 1:1000, #9271, Cell Signaling Technologies, Beverly, MA), anti-
ERK1 (1:2000, sc-94, Santa Cruz Biotechnology, Inc. Santa Cruz CA, USA) and anti-phospho-ERK (1:1000, sc-7303, Santa Cruz Biotechnology, Inc. Santa Cruz CA, USA). Membranes were incubated with corresponding horseradish peroxidase-conjugated secondary antibody (1:10,000) and were developed using a chemiluminescent reagent (ECL detection reagent, Amersham Biosciences). Developed signals were recorded on X-ray film (Fujifilm) for densitometric analysis (Scion Image Frederick, Maryland USA).

Quantification of renal mTOR, Akt and TGFβ1 by quantitative Real-Time PCR (qRT-PCR)

Total RNA was obtained following the Trizol manufacturer’s instructions (Invitrogen, Carlsbad). The RNA used for the study had a 26 s/18 s ratio between 1.8 and 2.0. Total RNA was reverse-transcribed as follows: 2 μg of RNA were incubated with 1 μl of 50 μM random hexamers followed by RNA denaturation at 70°C. Then, 5 μl reaction buffer, 0.4 μl of 100 mM dNTP mix, and MMLV reverse transcriptase (3 μl, Promega, Madison, WI, USA) were added in a final volume to 20 μl and the reaction was incubated during 5 min at 25°C, followed by 30 min at 42°C and 5 min at 85°C to stop the reaction. qRT-PCR was performed using 5 μl of cDNA, primers and the TaqMan probe for Akt (Rn-00583646_m1), mTOR (Rn-00571541) and TGFβ1 (Rn-00572010_m1). It is directed to focus gene NM 021578 that codifies for the translated protein NP_067589, precursor of total TGFβ1 (Aplied Biosystems, CA, USA) and the ABI Prism 7700 Sequence Detector. The level of target gene expression was determined using the ΔΔCt method as described [30] normalized to the Actin control (Applied Biosystems, Madrid, Spain). Results were expressed as ‘many fold of the unknown sample’ relative to the reference value (sham group). Triplicates were done in each experiment. Results are expressed as mean ± SEM.

Statistical analysis

All data were expressed as Mean ± SD. One way analysis of variance and post hoc with Student-Newman–Keuls test was used to determine the statistical significance. Statistical significance was defined as P value less than 0.05.

Acknowledgments

This work was made possible by the invaluable technical assistance of S. Ravaglio, A. Valega, A. Pérez and Dr. C. Mier. The results presented in this paper have not been published previously in whole or part, except in abstract format at ASN Meeting [J Am Soc Nephrol 18:402A 2007] and at the World Congress of Nephrology, Milan 2009.

Author Contributions

Conceived and designed the experiments: MK JG FGM JT MAA JMLN ON. Performed the experiments: MK ON JB IHP FGB NL LM MTG. Analyzed the data: MK VC JB MAA JMLN ON. Contributed reagents/materials/analysis tools: JMLN MAA JG JJ ON. Wrote the paper: ON MK JG MAA JB JMLN.

References

1. Dunn C, Croom KF (2006) Erolimus: a review of its use in renal and cardiac transplantation. Drugs 66: 547–570.
2. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, et al. (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326–2333.
3. Kaneki HK, Terasaki PI (2006) Thirty year trend in kidney transplants: UCLA experience. J Am Soc Nephrol 17: 1395–1404.
4. Ponticelli C (2008) Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transplantation 86: 1194–1200.
5. Li C, Yang CW (2009) The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 5: 319–328.
6. Eddy AA (2005) Progression in chronic kidney disease. Adv Chronic Kidney Dis 12: 353–365.
7. Grande ST, Lopez-Novoa JM (2009) Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 5: 319–328.
8. Nathi KA (1992) Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20: 1–17.
9. Strutz F, Muller GA (2006) Renal fibrosis and the origin of the renal fibroblast. Nephrol Dial Transplant 21: 12–18.
10. Sarbasboz DD, Guettin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101.
11. Letavernier E, Legendre C (2008) mTOR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) 22: 125–130.
12. Diekmann F, Gutierrez-Dahmna A, Lopez S, Cofan F, Esforzado N, et al. (2007) Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transplant 22: 2316–2321.
13. Morales J, Fierro A, Benavente D, Zehnder C, Farrarrio M, et al. (2007) Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria. Transplant Proc 39: 591–593. S0041-1345(06)01575-9.
14. Vollenbroek B, George B, Wollgatt M, Saleem MA, Pavenstadt H, et al. (2009) Mammalian target of rapamycin inhibition causes tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 54: 864–876.
15. Gadola L, Nooba O, Marquez MN, Rodriguez MJ, Nin N, et al. (2004) Calcium citrate ameliorates the progression of chronic renal injury. Kidney Int 65: 1294–1299.
16. Junaid A, Rosenberg ME, Hostetter TH (1997) Interaction of angiotensin II and TGF-beta 1 in a rat renal injury. J Am Soc Nephrol 8: 1732–1738.
17. Diekmann F, Rovira J, Carreras J, Arrullano EM, Banon-Manres E, et al. (2007) Mammalian target of rapamycin inhibition has the prognosis of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 18: 2653–2660.
18. Rovira J, Arrullano EM, Carreras J, Campos B, Vodenik B, et al. (2009) Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction. Transplantation 88: 646–652.
19. Zafar I, Belha FA, He Z, Edelstein CL (2009) Long-term rapamycin therapy in the Han.SPRID rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 24: 2349–2353.
20. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18: 1926–1945.
21. Rahimi RA, Andrianifahanana M, Wilkes MC, Edens M, Kotton TJ, et al. (2009) Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta. Cancer Res 69: 84–93.
22. Tabl MW, Chertow GM, Reimke HG, Garuani J, Tung T, et al. (2001) Mechanism underlying renoprotection during renin-angiotensin system blockade. Am J Physiol Renal Physiol 280: F142–F149.
23. Böttiger EP, Böer M (2002) TGF-beta signaling in renal disease. J Am Soc Nephrol 13: 2600–2610.
24. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF (2004) Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 65: 1262–1271.
25. Wang S, Wilkes MC, Loef EB, Hirschberg R (2010) Noncanonical TGF-beta pathways, mTORC1 and Akt in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 298: F142–F149.
26. Sarbasboz DD, Ali SM, Sengupta S, Sheer JH, Hu PP, et al. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159–161.
27. Liebenthal W, Levine JS (2009) The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 20: 2495–2502.
34. Lieberthal W, Fuhr R, Andry CC, Remke H, Abernathy VE, et al. (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281: F693–F706.
35. McTaggart RA, Gontier D, Brooks J, Bacchetti P, Roberts JP, et al. (2003) Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 3: 416–423. 078.
36. Letavernier E, Bruneval P, Mandet C, Van Huyen JP, Perrillié MN, et al. (2007) High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2: 526–533.
37. Nakagawa S, Masuda S, Nishihara K, Inui K (2010) mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochem Pharmacol 79: 67–76.
38. Bonegio RG, Fuhr R, Wang Z, Valeri CR, Andry C, et al. (2005) Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16: 2063–2072.
39. Rangan GK, Coombes JD (2007) Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. Nephrol Dial Transplant 22: 2175–2182.
40. Wu MJ, Wen MC, Chiu YT, Chien YY, Shu KH, et al. (2006) Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 69: 2029–2036.
41. Tao Y, Kim J, Schier R, Edelstein CL, (2005) Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46–51.
42. Krainer S, Wang-Rosenke Y, Scholl V, Binder E, Loef T, et al. (2008) Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 294: F440–F449.
43. Turpeinen U, Koivunen E, Steinman UH (1987) Liquid-chromatographic determination of beta 2-microglobulin, alpha 1-acid glycoprotein, and albumin in urine. Clin Chem 33: 1756–1760.
44. Zhang G, Oldroyd SD, Huang LH, Yang B, Li Y, et al. (2001) Role of apoptosis and Bcl-2/Bax in the development of tubulointerstitial fibrosis during experimental obstructive nephropathy. Exp Nephrol 9: 71–80.
45. Veniant M, Heudes D, Clozel JP, Brunevval P, Menard J (1994) Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. Kidney Int 46: 421–429.
46. Masseroli M, O'Valle F, Andujar M, Ramirez C, Gomez-Morales M, et al. (1998) Design and validation of a new image analysis method for automatic quantification of interstitial fibrosis and glomerular morphology. Lab Invest 78: 511–522.
47. Flores O, Arevalo M, Gallego B, Hidalgo F, Vidal S, et al. (1998) Beneficial effect of the long-term treatment with the combination of an ACE inhibitor and a calcium channel blocker on renal injury in rats with 5/6 nephrectomy. Exp Nephrol 6: 39–49.
48. Schanstra JP, Neae E, Drogou P, Arevalo Gomez MA, Lopez Novoa JM, et al. (2002) In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110: 371–379.
49. Grande MT, Fuentes-Calvo I, Arevalo M, Heredia F, Santos E, et al. (2010) Deletion of H-Ras decreases renal fibrosis and myofibroblast activation following ureteral obstruction in mice. Kidney Int 77: 509–518.
50. Herrero-Fresneda I, Torras J, Lloberas N, Riera M, Cruzado JM, et al. (2000) Cold ischemia in the absence of alloreactivity induces chronic transplant nephropathy through a process mediated by the platelet-activating factor. Transplantation 70: 1624–1631.